Oncology drugs are developing at a fast pace, but 2018 was the year when immune-oncology set new standards for several of the most common forms of the disease.
NICE has finalised its guidance recommending interim NHS funding for Gilead’s Yescarta CAR-T therapy, to treat patients with aggressive forms of non-Hodgkin lymphoma.
Novartis is focusing on cutting manufacturing costs for its CAR-T cancer cell therapy as the company launches it across Europe, while keeping a watching brief on ‘off-the-shelf’ therapies t
China has carved itself a place as a major player in the pharma industry due to the number of clinical trials it is running, thanks to the reforms it has put in place.
NICE has said Novartis’ CAR-T therapy Kymriah cannot be funded by the NHS in adults with an aggressive form of lymphoma, calling for further discussions to get the drug on to the market.